|
| | Issue Date | Title | Author(s) |
| 1 | 15-Apr-2023 | A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies | Chee, Cheng E ; Ooi, Melissa ; Lee, Soo-Chin ; Sundar, Raghav ; Heong, Valerie; Yong, Wei-Peng ; Ng, Chin Hin ; Wong, Andrea; Lim, Joline SJ ; Tan, David SP ; Soo, Ross ; Tan, Joshua TC; Yang, Song; Thura, Min; Al-Aidaroos, Abdul Qader; Chng, Wee Joo ; Zeng, Qi ; Goh, Boon-Cher |
| 2 | 1-Aug-2012 | Awaiting a new era of cancer immunotherapy | Hong, C.W.; Zeng, Q. |
| 3 | Feb-2012 | Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice | Guo, K.; Tang, J.P.; Jie, L.; Al-Aidaroos, A.Q.O.; Hong, C.W.; Tan, C.P.B.; Park, J.E.; Varghese, L.; Feng, Z.; Zhou, J. ; Chng, W.J.; Zeng, Q. |
| 4 | 1-Aug-2013 | Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells | Al-Aidaroos, A.Q.O.; Yuen, H.F.; Guo, K.; Zhang, S.D.; Chung, T.-H. ; Chng, W.J.; Zeng, Q. |
| 5 | 1992 | Neuropeptide gene expression in transgenic animals | Murphy, D. ; Ang, H.-L. ; Zeng, Q. ; Ho, M.-Y. ; Funkhouser, J. ; Carter, D. |
| 6 | Sep-2013 | Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia | Park, J.E.; Yuen, H.F.; Zhou, J.B. ; Al-aidaroos, A.Q.O.; Guo, K.; Valk, P.J.; Zhang, S.D.; Chng, W.J.; Hong, C.W.; Mills, K.; Zeng, Q. |
| 7 | 1-Dec-2010 | PRL-3 phosphatase and cancer metastasis | Al-Aidaroos, A.Q.O.; Zeng, Q. |
| 8 | 18-Feb-2013 | PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells | Liu, H.; Al-aidaroos, A.Q.O.; Wang, H.; Guo, K.; Li, J.; Zhang, H.F.; Zeng, Q. |
| 9 | 2019 | PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein | Thura M.; Al-Aidaroos A.Q.; Gupta A. ; Chee C.E. ; Lee S.C. ; Hui K.M. ; Li J.; Guan Y.K. ; Yong W.P. ; So J. ; Chng W.J. ; Ng C.H. ; Zhou J. ; Wang L.Z. ; Yuen J.S.P. ; Ho H.S.S. ; Yi S.M.; Chiong E. ; Choo S.P. ; Ngeow J. ; Ng M.C.H. ; Chua C. ; Yeo E.S.A. ; Tan I.B.H. ; Sng J.X.E.; Tan N.Y.Z.; Thiery J.P. ; Goh B.C. ; Zeng Q. |
| 10 | 29-Apr-1993 | Regulation of the extent of polyadenylation of vasopressin and growth hormone mRNAs in response to physiological stimuli | Waller, S.J. ; Carter, D.A. ; Ang, H.-L. ; Ho, M.-Y. ; Zeng, Q. ; Murphy, D. |
| 11 | 21-Jan-2014 | Tapping the treasure of intracellular oncotargets with immunotherapy | Hong, C.W.; Zeng, Q. |
| 12 | 7-Sep-2011 | Targeting intracellular oncoproteins with antibody therapy or vaccination | Guo, K.; Li, J.; Tang, J.P.; Tan, C.P.B.; Hong, C.W.; Al-Aidaroos, A.Q.O.; Varghese, L.; Huang, C.; Zeng, Q. |
| 13 | 29-Jan-2013 | TAZ Expression as a Prognostic Indicator in Colorectal Cancer | Yuen, H.-F.; McCrudden, C.M.; Huang, Y.-H.; Tham, J.M.; Zhang, X.; Zeng, Q. ; Zhang, S.-D.; Hong, W.J. |
